Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL By Ogkologos - June 9, 2026 15 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the frontMIND study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR African American Men More Likely to Die from Low-Grade Prostate Cancer January 28, 2019 Time to take on 9 new Cancer Grand Challenges March 8, 2023 Long-Term Responders with No Evidence of Disease Have Better Survival to... May 16, 2022 GreaterGood Partners with Organization of Hope to Deliver Toys and Necessities... January 5, 2022 Load more HOT NEWS Immune Responses Similar for Adjuvanted and Standard Dose Influenza Vaccines for... ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk... Genetic Counseling for Hereditary Breast Cancer: What People With a Family... Rusfertide Nearly Eliminates Need for Phlebotomies to Treat Polycythemia Vera
